Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Receivables - Net: 2015-2025

Historic Receivables - Net for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to $31.2 million.

  • Aytu Biopharma's Receivables - Net rose 43.46% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 43.46%. This contributed to the annual value of $31.2 million for FY2025, which is 22.91% up from last year.
  • Per Aytu Biopharma's latest filing, its Receivables - Net stood at $31.2 million for FY2025, which was up 22.91% from $25.3 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Receivables - Net ranged from a high of $31.7 million in FY2023 and a low of $24.2 million during FY2022.
  • Over the past 3 years, Aytu Biopharma's median Receivables - Net value was $31.2 million (recorded in 2025), while the average stood at $29.4 million.
  • As far as peak fluctuations go, Aytu Biopharma's Receivables - Net surged by 438.35% in 2021, and later dropped by 20.14% in 2022.
  • Aytu Biopharma's Receivables - Net (Yearly) stood at $30.3 million in 2021, then fell by 20.14% to $24.2 million in 2022, then skyrocketed by 30.96% to $31.7 million in 2023, then declined by 20.08% to $25.3 million in 2024, then rose by 22.91% to $31.2 million in 2025.